New vaccine combo aims to outsmart aggressive childhood cancer
NCT ID NCT04936529
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 4 times
Summary
This study tests whether a bivalent vaccine, taken with a sugar called beta-glucan and a protein (GM-CSF), can help prevent high-risk neuroblastoma from returning in children who are currently in remission. The treatment works by training the immune system to recognize and attack cancer cells. About 286 participants will be enrolled to see if adding GM-CSF improves the immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma